Effectiveness of Wearable Digital Therapeutics in Improving Sleep Outcomes Among Individuals With Insomnia: Systematic Review and Meta-Analysis of Randomized Controlled Trials - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Efficacy of Wearable Digital Therapeutics in Enhancing Sleep Quality for Individuals with Insomnia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Clinical Scorecard: Efficacy of Wearable Digital Therapeutics in Enhancing Sleep Quality for Individuals with Insomnia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
At a Glance
Category
Detail
Condition
Insomnia
Key Mechanisms
Persistent difficulty initiating or maintaining sleep with significant daytime impairment.
Target Population
Adults, particularly older adults and women.
Care Setting
Clinical settings focusing on sleep disorders.
Key Highlights
Insomnia affects approximately 10% to 20% of adults globally.
Prevalence increases with age; women are 1.3 to 1.7 times more likely to be affected than men.
Insomnia is a major risk factor for mental disorders and linked to reduced quality of life.
Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment.
Prolonged use of benzodiazepines carries risks such as dependence and cognitive impairment.
Guideline-Based Recommendations
Diagnosis
Insomnia is diagnosed based on persistent sleep difficulties and daytime impairment.
Management
Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment.
Monitoring & Follow-up
Monitor for risks associated with prolonged use of pharmacological treatments.
Risks
Benzodiazepine use can lead to dependence, cognitive impairment, and increased fall risk.
Patient & Prescribing Data
Individuals with insomnia, particularly older adults.
Access to CBT-I is limited due to a shortage of trained therapists and high costs.
Clinical Best Practices
Prioritize non-pharmacological interventions like CBT-I for insomnia management.
Evaluate the risks of pharmacological treatments before prescribing.
Increases in apnea-hypopnea events were greatest among patients with an elevated baseline index, while evidence supporting mouth taping remained preliminary.
